Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BMS-986012 + carboplatin + etoposide + nivolumab vs carboplatin + etoposide + nivolumab in first-line extensive-stage small cell lung cancer
2020-001863-10Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Atigotatug, nivolumab, carboplatin and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of adverse events. Started Mar 2021; status: active.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-001863-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001863-10.